Seikagaku up 5.9% in 2Q19 on US Reimbursement


Seikagaku grew in the mid-single digits on increased volumes of their Gel-One viscosupplement and favorable reimbursement decisions from U.S. insurers.

Domestic shipments of ARTZ decreased in volume, but were partially offset by delayed orders from previous quarters
International sales of the Gel-One viscosupplement...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us